pdf   xlsx method abbreviations

metastatic/advanced hepatocellular cancer (mHCC), durvalumab plus tremelimumab , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.78 [0.65, 0.93]< 10%1 study (1/-)99.7 %NAnot evaluable crucial-
deaths (OS) (extension) 0.78 [0.67, 0.91]< 10%1 study (1/-)99.9 %NAnot evaluable important-
progression or deaths (PFS) 0.90 [0.77, 1.05]< 10%1 study (1/-)90.9 %NAnot evaluable important-

safety endpoints 00

AE (any grade) 1.80 [0.81, 3.98]< 10%1 study (1/-)7.4 %NAnot evaluable non important-
AE (grade 3-4) 2.42 [1.80, 3.26]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
AE leading to death (grade 5) 1.08 [0.63, 1.85]< 10%1 study (1/-)39.4 %NAnot evaluable non important-
AE leading to treatment discontinuation (any grade) 0.78 [0.53, 1.16]< 10%1 study (1/-)88.9 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons